Home » Newsletters » BioWorld Science

BioWorld Science

April 19, 2005

View Archived Issues

New data on the pharmacokinetics and metabolism of viramidine

Atorvastatin prevents autoimmune disease by interfering with Ras and Rho GTPase prenylation

EGCG exerts neuroprotective and antiinflammatory actions in murine EAE

Monoclonal antibodies prevent hepatitis C viral reinfection

GB Therapeutics changes name to Cita NeuroPharmaceuticals

Therapeutic potential of the histamine H3 receptor antagonist ABT-239

Leinamycin prodrug activated by oxidative stress in prostate tumor cells

Xsira inlicenses adenosine for reduction of postoperative pain

Target selection in Celera Genomics and Abbott collaboration

NDA resubmission for indiplon capsules

FDA ready to review OrCel PMA application

Positive findings in proof-of-principle study for COL-3 in rosacea

Genentech extends support of Curis collaborative efforts

U.K. clearance for phase IIb CoFactor study in metastatic colorectal cancer

2ME2 receives orphan drug designation for ovarian cancer

Phase I study begins dosing for intranasal RSV vaccine

Lundbeck looks back at 2004

First small-molecule agonists of orphan estrogen-related receptors synthesized

PharmaFrontiers updates recent progress

Second year of SBIR funding supports GelVac evaluation

FDA approval of Liberte stent

New treatments for diabetes claimed by Arena

Antiobesity drugs disclosed in patents from Banyu and BMS

Bionaut and AnalytiCon Discovery sign lead optimization agreement for cancer

REP-9: A highly potent broad-spectrum antiviral agent

Selective dual-specificity phosphatase inhibitors with potential as anticancer agents

Novel mechanism of antitumor activity demonstrated for NK-314

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 4, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 4, 2025.
First phase of synthetic human genome project successfully completes
BioWorld
The first phase of the U.K. synthetic human genome project has successfully completed, realizing key steps in chromosome synthesis. The work has demonstrated a...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Laigo raises €11.5M seed money for targeted protein degradation
BioWorld Science
Laigo Bio BV has raised €11.5 million (US$13.7 million) in a seed round for the further development of a new approach to inducing targeted protein degradation by...